EA200700391A1 - Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 - Google Patents
Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1Info
- Publication number
- EA200700391A1 EA200700391A1 EA200700391A EA200700391A EA200700391A1 EA 200700391 A1 EA200700391 A1 EA 200700391A1 EA 200700391 A EA200700391 A EA 200700391A EA 200700391 A EA200700391 A EA 200700391A EA 200700391 A1 EA200700391 A1 EA 200700391A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- transferrin
- slip
- application
- combined treatment
- proteins containing
- Prior art date
Links
- 102000004338 Transferrin Human genes 0.000 title abstract 3
- 108090000901 Transferrin Proteins 0.000 title abstract 3
- 239000012581 transferrin Substances 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59803104P | 2004-08-03 | 2004-08-03 | |
| PCT/US2005/027800 WO2006017688A2 (fr) | 2004-08-03 | 2005-08-03 | Polythérapie basée sur l’utilisation de protéines hybrides de transferrine contenant du glp-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200700391A1 true EA200700391A1 (ru) | 2007-10-26 |
Family
ID=35839920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200700391A EA200700391A1 (ru) | 2004-08-03 | 2005-08-03 | Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1814599A4 (fr) |
| JP (1) | JP2008509153A (fr) |
| KR (1) | KR20070085224A (fr) |
| CN (1) | CN101035568A (fr) |
| AP (1) | AP2007003920A0 (fr) |
| AU (1) | AU2005271403A1 (fr) |
| BR (1) | BRPI0514115A (fr) |
| CA (1) | CA2575756A1 (fr) |
| CR (1) | CR8954A (fr) |
| EA (1) | EA200700391A1 (fr) |
| GB (1) | GB2431583A (fr) |
| IL (1) | IL181108A0 (fr) |
| MA (1) | MA28843B1 (fr) |
| MX (1) | MX2007001424A (fr) |
| NO (1) | NO20071018L (fr) |
| RU (1) | RU2007107808A (fr) |
| TN (1) | TNSN07039A1 (fr) |
| WO (1) | WO2006017688A2 (fr) |
| ZA (1) | ZA200701484B (fr) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| ATE385193T1 (de) | 2002-03-20 | 2008-02-15 | Mannkind Corp | Inhalationsgerät |
| CA2575692C (fr) | 2004-08-20 | 2014-10-14 | Mannkind Corporation | Catalyse de la synthese de dicetopiperazine |
| BR122019022692B1 (pt) | 2004-08-23 | 2023-01-10 | Mannkind Corporation | Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo |
| JP2008531059A (ja) * | 2005-03-04 | 2008-08-14 | バイオレクシス ファーマシューティカル コーポレーション | 改変トランスフェリン融合タンパク質 |
| DK1937219T3 (en) | 2005-09-14 | 2016-02-15 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles |
| IN2015DN00888A (fr) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| CA2646598C (fr) * | 2006-03-21 | 2014-08-19 | Amylin Pharmaceuticals, Inc. | Conjugues inhibiteur de peptidase-peptide et procedes d'utilisation de ceux-ci |
| WO2008012629A2 (fr) * | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Protéines de fusion d'extendine |
| WO2008033395A2 (fr) * | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Protéines de fusion mélanocortine et transferrine |
| EP2195034A2 (fr) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Conjugués inhibiteurs de peptide/peptidase et leurs procédés de fabrication et d'utilisation |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| KR101933816B1 (ko) | 2008-06-13 | 2019-03-29 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
| EP2609954B1 (fr) | 2008-06-20 | 2021-12-29 | MannKind Corporation | Appareil interactif pour l'établissement en temps réel d'un profil des efforts d'inhalation |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| MY157166A (en) | 2009-06-12 | 2016-05-13 | Mankind Corp | Diketopiperazine microparticles with defined specific surface areas |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| WO2012026526A1 (fr) | 2010-08-27 | 2012-03-01 | 国立大学法人宮崎大学 | Récepteur d'hémokinine 1 et peptide dérivé d'hémokinine 1 |
| JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
| WO2012174472A1 (fr) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | Microparticules de dicétopipérazine de capacité élevée |
| RU2477726C1 (ru) * | 2011-10-18 | 2013-03-20 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение |
| CA2852536A1 (fr) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Procedes et compositions pour traiter la douleur |
| CN103160565A (zh) * | 2011-12-09 | 2013-06-19 | 彩虹天健康科技研究(北京)有限责任公司 | Unc-51激酶影响细胞运铁蛋白的胞吞作用 |
| US9809641B2 (en) | 2012-04-23 | 2017-11-07 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
| ES2624294T3 (es) | 2012-07-12 | 2017-07-13 | Mannkind Corporation | Sistemas de suministro de fármacos en polvo seco |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP2911690A1 (fr) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Compositions et procédés de vaccin antigrippal inhalable |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| EP2970149B1 (fr) | 2013-03-15 | 2019-08-21 | MannKind Corporation | Compositions de dicétopipérazine microcristallines et procédés |
| CN103275177B (zh) * | 2013-06-24 | 2015-08-12 | 南京财经大学 | 具有肾素和ace双重抑制活性的小肽、其制备方法及应用 |
| BR112016000937A8 (pt) | 2013-07-18 | 2021-06-22 | Mannkind Corp | formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco |
| CA2920488C (fr) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Appareil d'insufflation et procedes |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| EP3080149A1 (fr) | 2013-12-13 | 2016-10-19 | Sanofi | Agonistes mixtes des récepteurs du glp-1/glucagon |
| WO2015086730A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Analogues peptidiques de l'exendine 4 non acylés |
| WO2015148905A1 (fr) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Utilisation d'insuline à action ultrarapide |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| CN111388680B (zh) * | 2015-01-28 | 2024-01-05 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| US11041014B2 (en) | 2016-10-28 | 2021-06-22 | S & K Biopharma, Inc. | Lactoferrin/albumin fusion protein and production method therefor |
| US11459368B2 (en) | 2017-07-14 | 2022-10-04 | Livactus, Inc. | Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance |
| CN112312922A (zh) * | 2018-06-21 | 2021-02-02 | 诺和诺德股份有限公司 | 用于治疗肥胖症的新型化合物 |
| CN110218259B (zh) * | 2019-06-24 | 2022-09-16 | 王跃驹 | 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用 |
| CN112661862B (zh) * | 2020-12-25 | 2023-03-31 | 深圳大学 | 一种融合蛋白及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US7285526B2 (en) * | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| AU2001290638C1 (en) * | 2000-09-06 | 2009-04-30 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| JP2005513165A (ja) * | 2002-01-11 | 2005-05-12 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病、高血圧、慢性心不全および体液貯留状態の治療のための方法および組成物 |
| AU2003270009A1 (en) * | 2002-08-30 | 2004-03-19 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
| ES2347144T3 (es) * | 2002-08-30 | 2010-10-26 | Biorexis Pharmaceutical Corporation | Proteinas de fusion de la transferrina modificada que comprenden dominos aino o carboxilo de transferrina duplicados. |
-
2005
- 2005-08-03 CN CNA2005800336740A patent/CN101035568A/zh active Pending
- 2005-08-03 JP JP2007525008A patent/JP2008509153A/ja not_active Withdrawn
- 2005-08-03 WO PCT/US2005/027800 patent/WO2006017688A2/fr active Application Filing
- 2005-08-03 EA EA200700391A patent/EA200700391A1/ru unknown
- 2005-08-03 EP EP05782173A patent/EP1814599A4/fr not_active Withdrawn
- 2005-08-03 CA CA002575756A patent/CA2575756A1/fr not_active Abandoned
- 2005-08-03 MX MX2007001424A patent/MX2007001424A/es not_active Application Discontinuation
- 2005-08-03 RU RU2007107808/14A patent/RU2007107808A/ru not_active Application Discontinuation
- 2005-08-03 KR KR1020077005257A patent/KR20070085224A/ko not_active Application Discontinuation
- 2005-08-03 ZA ZA200701484A patent/ZA200701484B/xx unknown
- 2005-08-03 AP AP2007003920A patent/AP2007003920A0/xx unknown
- 2005-08-03 BR BRPI0514115-0A patent/BRPI0514115A/pt not_active IP Right Cessation
- 2005-08-03 AU AU2005271403A patent/AU2005271403A1/en not_active Abandoned
-
2007
- 2007-02-01 IL IL181108A patent/IL181108A0/en unknown
- 2007-02-02 TN TNP2007000039A patent/TNSN07039A1/fr unknown
- 2007-02-22 NO NO20071018A patent/NO20071018L/no not_active Application Discontinuation
- 2007-02-26 GB GB0703685A patent/GB2431583A/en not_active Withdrawn
- 2007-03-02 MA MA29727A patent/MA28843B1/fr unknown
- 2007-03-02 CR CR8954A patent/CR8954A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2431583A (en) | 2007-05-02 |
| IL181108A0 (en) | 2007-07-04 |
| AU2005271403A1 (en) | 2006-02-16 |
| WO2006017688A2 (fr) | 2006-02-16 |
| CR8954A (es) | 2007-10-02 |
| GB0703685D0 (en) | 2007-04-04 |
| JP2008509153A (ja) | 2008-03-27 |
| TNSN07039A1 (fr) | 2008-06-02 |
| CN101035568A (zh) | 2007-09-12 |
| NO20071018L (no) | 2007-04-11 |
| RU2007107808A (ru) | 2008-09-10 |
| MX2007001424A (es) | 2008-03-13 |
| CA2575756A1 (fr) | 2006-02-16 |
| EP1814599A4 (fr) | 2008-12-17 |
| KR20070085224A (ko) | 2007-08-27 |
| MA28843B1 (fr) | 2007-09-03 |
| AP2007003920A0 (en) | 2007-02-28 |
| EP1814599A2 (fr) | 2007-08-08 |
| BRPI0514115A (pt) | 2008-05-27 |
| WO2006017688A3 (fr) | 2006-08-03 |
| ZA200701484B (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200700391A1 (ru) | Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 | |
| EA200702208A1 (ru) | Ингибиторы дипептидилпептидазы-iv | |
| WO2004078777A3 (fr) | Proteines protegees contre la dipeptidylpeptidase | |
| DK1692158T3 (da) | VEGF-binding og understøttede peptider til behandling af hudsygdomme | |
| WO2009147248A3 (fr) | Séquences d'acides aminés dirigées contre des protéines d'enveloppe d'un virus, et polypeptides comprenant ces séquences destinés au traitement de maladies virales | |
| EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
| GEP20105111B (en) | Rage fusion proteins and methods of use | |
| EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| EA200600869A1 (ru) | Антитела, связывающие рецептор интерлейкина-4 | |
| ATE525395T1 (de) | Fusions proteine von glp-1-analoga | |
| IS7753A (is) | Beta-amínó heterósýklískir dípeptidýl peptíðasa hindrar til meðhöndlunar á, eða til að fyrirbyggja,sykursýki | |
| ME00185B (me) | Specifični agensi koji vezuju humani angiopoetin-2 | |
| DE60330767D1 (de) | Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen | |
| ECSP088962A (es) | Nuevos herbicidas | |
| GEP20115324B (en) | Tweak binding antibodies | |
| EA201100071A1 (ru) | Новые композиции и способы | |
| AR057614A1 (es) | Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| EA200600735A1 (ru) | Нуклеиновые кислоты, специфично связывающие биоактивный грелин | |
| IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
| CY1109631T1 (el) | Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ | |
| DK1687267T3 (da) | Modificeret MscL-proteinkanal | |
| WO2005059131A3 (fr) | Proteine fixant des proteines en miniature et leurs applications | |
| EA200501711A1 (ru) | Семейство секретируемых белков |